logo
Plus   Neg
Share
Email

Xstrata, Glencore In Constructive Talks With Regulators On Merger - Update

Xstrata Plc (XTA.L) and Glencore International Plc (GLEN.L,GLNCY.PK,GLCNF.PK) on Friday said they are currently engaged in constructive discussions with the regulatory authorities, including the European Commission, which require anti-trust filings to be submitted for their proposed merger.

It was on February 7 that the Swiss mining company unveiled an all-share merger of equals with its 34-percent stakeholder Glencore. The merger, dubbed the 'logical next step for two complementary businesses' would create a $90 billion natural resources group to be called Glencore Xstrata International Plc.

Following the deal, Xstrata shareholders other than Glencore would have a 45 percent stake in the combined entity.

The companies today said they continue to expect to receive all relevant approvals to enable completion of the merger in the third quarter, as previously announced.

Documentation relating to the merger is now anticipated to be distributed to each company's shareholders by the end of May instead of in April as previously said on February 7.

Shareholder meetings of both companies to approve the merger are expected to be convened in early July.

The Panel on Takeovers and Mergers has given its consent to these arrangements, the company noted.

XTA.L closed on Thursday at 1,105.50 pence, up 26.50 pence from the previous close.

Glencore shares settled higher by 2.51 percent on the LSE at 404.90 pence.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT